DISCOVERY
Uncover breakthrough
innovations during the drug
discovery phase.
innovations during the drug
discovery phase.
Carolina Ahrendt has over 20 years of experience in program and portfolio management for developing pharmaceuticals and biologics across multiple therapeutic areas. She has provided program leadership in all phases of development and managed numerous INDs, BLAs, and NDAs. She has extensive knowledge in guiding cross-functional teams with strategic planning, marketing application preparation, and integrated development plan analysis throughout the product life cycle (from early to late stage development). Carolina has supported programs in therapeutic areas such as diabetes, inflammation, oncology, ophthalmology, pain, rare diseases, schizophrenia, and viruses.
Before joining Halloran, Carolina held a leadership position in regulatory project management at EVERSANA’s consulting division. In this role, she managed several original IND applications and IND maintenance projects, liaised between the Sponsor and FDA Regulatory Project Manager, and supported the preparation for various FDA meetings. Before that, she was a Development Program Manager at Array BioPharma progressing clinical development programs from candidate nomination, Phase 1, 2, 3, and NDA for various products in the pipeline. Her role included facilitating cross-functional collaboration, managing alliances and partnerships, and high-level stakeholder communications. Earlier in her career, Carolina was a formulation scientist and analytical chemist at Array BioPharma and Geneva Pharmaceuticals.
Education:
Colorado State University, Master of Business Administration (MBA)
University of Colorado Boulder, Bachelor of Arts, Biochemistry, Chemistry, and Biology
